► Subscribe for new videos every day!: http://bit.ly/dai_youtube ► Dave Van Knapp's Top 30 Dividend Growth Stocks for 2021: https://DaveVanKnapp.com/ ► Dave Van Knapp's Dividend Growth Portfolio: https://dailytradealert.com/dave-van-knapps-dividend-growth-portfolio/ ► Prefer to Read? https://dividendsandincome.com/2021/07/30/dividend-growth-stock-of-the-month-for-august-2021-bristol-myers-squibb-bmy/ Bristol-Myers Squibb (BMY) is a pharmaceutical giant. Its mission is elegantly stated: Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. How does BMY check out as a dividend-growth investment? Let’s take a look, beginning with its dividend. BMY’s Dividend Record BMY is a mid-yield, mid-growth DG stock. BMY’s most attractive dividend features are its decent yield, safe dividend, and the recent acceleration in its dividend growth rate. The safety of its dividend is indicated by its 79/100 safety score from Simply Safe Dividends. That score was just reaffirmed in May, after the company’s first-quarter earnings release. The score is just two points short of a Very Safe rating. The graphs in the video from Simply Safe Dividends illustrate that BMY is not paying out an excessive share of its profits or cash flow, which means that it appears to have a good runway for maintaining and increasing its dividend. BMY’s most recent dividend increase (paid in early 2021) was 8.9%. If the company were to maintain that rate of increase for a couple more years, I would reclassify it as a mid-yield, fast-growth stock. In the spreadsheet snip in the video, you can see the acceleration of BMY’s dividend growth rate over the past few years. The Bottom Line on Bristol-Myers Squibb BMY’s Positives: Mid-yield, mid-growth stock with safe dividend. Recent dividend increases have been growing, with most recent at 8.9%. Safe dividend-safety grade of 79. Excellent business model with sustainable competitive advantages. High quality ratings from third-party providers. Good financials, with excellent cashflow. Management has indicated intent to reduce debt associated with recent major acquisitions. Seems to be successfully absorbing acquisitions, which have broadened company’s scope and product lines. About 10% undervalued. BMY’s Negatives: Recent significant increases in debt and shares outstanding related to major acquisitions. Management has stated intent to reduce debt. Conclusion: In my opinion, BMY is a fine candidate for dividend-growth investors who are looking for a strong, stable company that offers dividend safety, and who do not insist on high yields. Years of flat price may be a “coiled spring” in relation to company’s true value. FOLLOW US: ► Website: http://www.dividendsandincome.com/ ► YouTube: http://bit.ly/dai_youtube #DGI #StockoftheMonth #DividendGrowthInvesting $BMY LEGAL DISCLAIMER: Please consult with a licensed investment professional before investing any of your money. Never invest in a security or idea featured on this channel unless you can afford to lose your entire investment. If your money is not FDIC insured, it may decline in value. Dave is not a licensed financial advisor, tax professional, or stockbroker and he does not purport to be. Links above may include affiliate commissions paid to the owners of Dividends and Income and help support this channel.